| Literature DB >> 32545826 |
Michael Doulberis1,2,3,4, Apostolis Papaefthymiou2,3,5, Stergios A Polyzos3, Panagiotis Bargiotas6, Christos Liatsos7, David Shiva Srivastava4, Christos Zavos2, Panagiotis Katsinelos2, Jannis Kountouras2.
Abstract
Background: Glaucoma is the second most common cause of blindness worldwide affecting almost 70 million individuals. Helicobacter pylori (H. pylori) is a widespread pathogen with systematic pathogenicity. This meta-analysis aimed to estimate the contradictory data regarding a potential association between active H. pylori infection and glaucoma. Materials andEntities:
Keywords: Helicobacter pylori infection; glaucoma; primary open-angle glaucoma; pseudo-exfoliation glaucoma
Year: 2020 PMID: 32545826 PMCID: PMC7355761 DOI: 10.3390/microorganisms8060894
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Flowchart based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines interpreting the selection process of the reviewed studies to insert in the meta-analysis.
The characteristics of the included studies.
| No | First Author | Year of Publication | Type of Study | Country (Region) | Host Journal | Glaucoma Cases | Controls | Mean Age (years) * | Controls Deposit | Glaucoma Subtype | MD of Anti- | NOS Score | Relationship between | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abrishami et al. | 2007 | Cohort | Iran (East) |
| 44 | 79 | 60.8 | Cataract | POAG | ELISA | N/A | N/A | 3.69 (1.68–8.13) |
| 2 | Deshpande et al. | 2008 | Case-control | India (East) |
| 50 | 50 | 63.7 | Cataract | POAG | ELISA | 20′220 | 8 | 1.20 (0.52–2.79) |
| 3 | Deshpande et al. | 2008 | Case-control | India (East) |
| 50 | 50 | 67 | Cataract | PEG | ELISA | −8′610 | 0.41 (0.18–0.91) | |
| 4 | Galloway et al. | 2003 | Cohort | Canada (West) |
| 38 | 94 | 63.2 | Healthy | POAG | ELISA | −10′600 | 8 | 1.41 (0.59–3.4) |
| 5 | Galloway et al. | 2003 | Cohort | Canada (West) |
| 16 | 94 | 73.2 | Healthy | PEG | ELISA | 18′500 | 1.32 (0.38–4.54) | |
| 6 | Galloway et al. | 2003 | Cohort | Canada (West) |
| 19 | 94 | 67.7 | Healthy | NTG | ELISA | 23′300 | 1.41 (0.45–4.4) | |
| 7 | Hong et al. | 2007 | Case-control | China (East) |
| 24 | 24 | 63.9 | Healthy | POAG | UBT | N/A | 8 | 4.49 (1.26–16) |
| 8 | Kim et al. | 2011 | Retrospective Cohort | South Korea (East) |
| 100 | 88 | 55.6 | Healthy | NTG | ELISA | N/A | 8 | 2.05 (1.12–3.75) |
| 9 | Kim et al. | 2011 | Retrospective Cohort | South Korea (East) |
| 104 | 1116 | 53.4 | Healthy | NTG | ELISA | N/A | 1.83 (1.17–2.86) | |
| 10 | Kountouras et al. | 2003 | Cohort | Greece (West) |
| 27 | 31 | 70.6 | Cataract | POAG | ELISA | 37′210 | 8 | 2.35 (0.63–8.76) |
| 11 | Kountouras et al. | 2003 | Cohort | Greece (West) |
| 19 | 31 | 69.2 | Cataract | PEG | ELISA | 25′800 | 25 (1.38–452.34) | |
| 12 | Kountouras et al. | 2002 | Cohort | Greece (West) |
| 41 | 30 | 61.4 | Anemia | POAG | HISTOLOGY | 18′570 | 8 | 8.23 (2.53–26.75) |
| 13 | Kountouras et al. | 2001 | Case-control | Greece (West) |
| 32 | 30 | 64 | Anemia | POAG | HISTOLOGY | N/A | 8 (2.25–28.48) | |
| 14 | Kountouras et al. | 2001 | Case-control | Greece (West) |
| 9 | 30 | 62 | Anemia | PEG | HISTOLOGY | N/A | 7 | 9.14 (1.01–82.44) |
| 15 | Kurtz et al. | 2008 | Cohort | Israel (West) |
| 13 | 36 | 67.7 | Cataract | POAG | ELISA | N/A | 8 | 0.74 (0.21–2.67) |
| 16 | Kurtz et al. | 2008 | Cohort | Israel (West) |
| 23 | 36 | Cataract | PEG | ELISA | N/A | 1.19 (0.4–3.54) | ||
| 17 | Kurtz et al. | 2008 | Cohort | Israel (West) |
| 15 | 36 | Cataract | NTG | ELISA | N/A | 0.96 (0.28–3.27) | ||
| 18 | Noche et al. | 2016 | Case-control | Cameroon (Africa) |
| 50 | 31 | 58.52 | Healthy | POAG | ELISA | N/A | 8 | 0.42 (0.12–1.43) |
| 19 | Samarai et al. | 2014 | Case-control | Iran (East) |
| 37 | 42 | 73.05 | Anemia | POAG | ELISA | N/A | 8 | 5.61 (1.68–18.75) |
| 20 | Sultana et al. | 2019 | Case-control | Bangladesh (East) |
| 40 | 40 | 51.4 | Healthy | POAG | ELISA | N/A | 8 | 3.89 (1.53–9.87) |
| 21 | Tsolaki et al. | 2015 | Cohort | Greece (West) |
| 35 | 31 | 62.18 | Healthy | POAG | HISTOLOGY | N/A | 7 | 2.65 (0.97–7.24) |
| 22 | Tuzcu et al. | 2015 | Case-control | Turkey (East) |
| 35 | 35 | 59.08 | Healthy | POAG | UBT | N/A | 8 | 1.41 (0.55–3.62) |
| 23 | Zavos et al. | 2012 | Case-control | Greece (West) |
| 51 | 35 | 71.4 | Anemia | POAG | HISTOLOGY | N/A | 8 | 5.69 (2.08–15.54) |
* refers to glaucoma group, CI; Confidence Interval, ELISA; Enzyme Linked Immunosorbent Assay, H. pylori; Helicobacter pylori, MD; Differences of Means, N/A; not available, NOS; Newcastle-Ottawa scale, NTG; Normal Tension Glaucoma, OAG; Open Angle Glaucoma. OR; Odds Ratio, PEG; Pseudo-Exfoliation Glaucoma,UBT; urea breath test.
Figure 2(a) Forest plot illustrating, in OR, the overall and per included study association between H. pylori infection and glaucoma risk. (b) Forest plot for the association between means of difference of anti- H. pylori antibodies titers and glaucoma occurrence. (c) Meta-regression scatter plot indicating the relationship between the means of difference of anti-H. pylori antibodies titers and glaucoma risk after adjustment for mean age. (d) Sensitivity analysis excluding our group’s studies and confirming the absence of bias because of our own studies. CI, confidence interval; H. pylori; Helicobacter pylori; NTG, normal tension glaucoma; OR, odds ratio; POAG, primary open angle glaucoma; PEG, pseudo-exfoliation glaucoma; MD, weighted mean differences.
Subgroup analysis regarding the relationship between H. pylori infection and glaucoma.
| Random Effects Model | Heterogeneity | |||||||
|---|---|---|---|---|---|---|---|---|
| Subgroup | Datasets | OR | CI 95% |
|
|
|
| |
| Total | 23 | 2.08 | 1.48–2.93 |
| 57.21 | 61.54 | 0.39 |
|
| Region | ||||||||
| EAST | 8 | 2.1 | 1.23–3.56 |
| 25.1 | 72.11 |
| |
| WEST | 14 | 2.32 | 1.47–3.64 |
| 25.51 | 49.04 |
| |
| AFRICA | 1 | 0.42 | 0.12–1.44 |
|
|
|
| |
| Glaucoma Subtype | ||||||||
| POAG | 14 | 2.57 | 1.66–3.99 |
| 31.59 | 58.85 |
| |
| PEG | 5 | 1.69 | 0.53–5.34 |
| 13.68 | 70.76 |
| |
| NTG | 4 | 1.76 | 1.27–2.46 |
| 1.36 | 0 |
| |
| Study Design | ||||||||
| Cohort | 13 | 1.98 | 1.44–2.74 |
| 17.24 | 30.4 |
| |
| Case-control | 10 | 2.33 | 1.13–4.81 |
| 39.95 | 77.47 |
| |
| Control groups | ||||||||
| Cataract | 8 | 1.37 | 0.7–2.67 |
| 20.52 | 65.89 |
| |
| Anemia | 5 | 6.78 | 3.88–11.83 |
| 0.45 | 0 |
| |
| Healthy | 10 | 1.82 | 1.33–2.5 |
| 11.7 | 23.07 |
| |
| ELISA | 16 | 1.57 | 1.09–2.28 |
| 35.35 | 57.57 |
| |
| UBT | 2 | 2.32 | 0.76–7.13 |
| 2.06 | 51.35 |
| |
| HISTOLOGY | 5 | 5.4 | 3.17–9.2 |
| 3.02 | 0 |
| |
CI; Condifence Interval, elisa Enzyme Linked Immunosorbent Assay, H. pylori; Helicobacter pylori, N/A; not available, NTG; Normal Tension Glaucoma, OAG; Open Angle Glaucoma, OR; Odds Ratio, PEG; Pseudo-Exfoliation Glaucoma, UBT; Urea Breath Test.
Figure 3Funnel plot for both study models. Despite the non-significant Egger and Begg tests, there is a visual asymmetry in the funnel plots, indicative of a degree of publication bias. MD; weighted mean differences, OR; odds ratio, SE; standard error.